Literature DB >> 22920640

Current approach to diagnosis and management of acute renal failure in myeloma patients.

Nelson Leung1, Judith Behrens.   

Abstract

Renal impairment is a serious complication of multiple myeloma. The primary cause of renal failure in myeloma is damage to the kidney by excessive amounts of light chain produced by the myeloma tumor, giving rise to cast nephropathy (myeloma kidney), although there are several other important precipitants. Significantly poor prognosis is observed in patients who do not recover their renal function; however, with the advent of more effective therapies and a greater understanding of the pathogenesis of the underlying process, it has become possible to reverse renal impairment in greater numbers of patients. Determining whether the renal impairment is due to cast nephropathy should be the first priority, and once the diagnosis is confirmed, appropriate treatment should be initiated without delay. Reduction of serum free light chain is the key to recovery of renal function in these patients. The role of chemotherapy and extracorporeal removal of light chain are discussed.
Copyright © 2012 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22920640     DOI: 10.1053/j.ackd.2012.06.001

Source DB:  PubMed          Journal:  Adv Chronic Kidney Dis        ISSN: 1548-5595            Impact factor:   3.620


  5 in total

Review 1.  Myeloma light chain cast nephropathy, a review.

Authors:  Insara Jaffer Sathick; Maria Eleni Drosou; Nelson Leung
Journal:  J Nephrol       Date:  2018-05-05       Impact factor: 3.902

2.  Bence Jones proteinuria in smoldering multiple myeloma as a predictor marker of progression to symptomatic multiple myeloma.

Authors:  V González-Calle; J Dávila; F Escalante; A G de Coca; C Aguilera; R López; A Bárez; J M Alonso; R Hernández; J M Hernández; P de la Fuente; N Puig; E M Ocio; N C Gutiérrez; R García-Sanz; M V Mateos
Journal:  Leukemia       Date:  2016-05-02       Impact factor: 11.528

Review 3.  Analysis of carfilzomib cardiovascular safety profile across relapsed and/or refractory multiple myeloma clinical trials.

Authors:  Ajai Chari; A Keith Stewart; Stuart D Russell; Philippe Moreau; Joerg Herrmann; Jose Banchs; Roman Hajek; John Groarke; Alexander R Lyon; George N Batty; Sunhee Ro; Mei Huang; Karim S Iskander; Daniel Lenihan
Journal:  Blood Adv       Date:  2018-07-10

4.  Severe renal impairment as an adverse prognostic factor for survival in newly diagnosed multiple myeloma patients.

Authors:  Xuduan Chen; Xiaofeng Luo; Yanping Zu; Hajji Ally Issa; Linlin Li; Hong Ye; Ting Yang; Jianda Hu; Lixin Wei
Journal:  J Clin Lab Anal       Date:  2020-07-25       Impact factor: 2.352

5.  Pharmacokinetics and Safety of Elotuzumab Combined With Lenalidomide and Dexamethasone in Patients With Multiple Myeloma and Various Levels of Renal Impairment: Results of a Phase Ib Study.

Authors:  Jesus Berdeja; Sundar Jagannath; Jeffrey Zonder; Ashraf Badros; Jonathan L Kaufman; Robert Manges; Manish Gupta; Amol Tendolkar; Mark Lynch; Eric Bleickardt; Prashni Paliwal; Ravi Vij
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2015-12-21
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.